ClinicalTrials.gg
Not yet recruitingNCT07479043Updated Oct 1, 2026

To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).

A Phase 3 interventional study of Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC. and Controls will receive two infusions of vehicle solution. in Acute Respiratory Distress Syndrome, sponsored by Breathe Biologics, Inc.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Breathe Biologics, Inc. · Phase 3, Interventional, and Treatment

How we know

Updated Oct 1, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). JadiCells are administered intravenously and are intended to modulate inflammatory responses and promote tissue repair in injured lung tissue.

Read the detailed description

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by severe inflammatory lung injury, impaired oxygen exchange, and high mortality. Current treatments are primarily supportive and include mechanical ventilation and intensive care management.

JadiCell™ is an investigational cellular therapy derived from human umbilical cord tissue. These cells possess immunomodulatory and regenerative properties and may reduce inflammatory lung injury through paracrine signaling, immune regulation, and tissue repair mechanisms.

Following intravenous administration, mesenchymal stem cells are known to localize within the pulmonary microvasculature where they interact with immune cells and injured lung tissue.

This study will evaluate the safety and potential clinical effects of intravenous JadiCell administration in patients with ARDS.

02

Conditions studied

  • Acute Respiratory Distress Syndrome

Keywords

  • Acute Respiratory Distress Syndrome
  • ARDS
  • Mesenchymal Stem Cells
  • Cell Therapy
  • Regenerative Medicine
  • Inflammation
03

In context

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

This study's planned enrollment of 128 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

This is the only study on the registry with Breathe Biologics, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients currently hospitalized
  2. Laboratory confirmation of ARDS
  3. Aged between 18 and 80 years
  4. Willing and able to provide written , or with a legal representative who can provide informed consent
  5. SpO2 \<94% on room air requiring supplemental oxygen above baseline
  6. PaO2/FiO2 \<300 mmHg
  7. Bilateral infiltrates on frontal chest radiograph or bilateral ground glass opacities on a chest CT scan
  8. Requiring one of the following ï High Flow Oxygen Therapy ï Non-invasive Positive Pressure Ventilation (NIPPV, e.g. BiPAP and CPAP) ï Invasive Mechanical Ventilation (INV = intubated)

Exclusion criteria

Exclusion Criteria:

  1. Greater than 96 h since hospitalization at the time of enrollment
  2. Greater than 48 h since intubation at the time of enrollment
  3. A previous MSC infusion not related to this trial
  4. History of Pulmonary Hypertension (WHO Class III/IV)
  5. History of left atrial hypertension or decompensated left heart failure.
  6. Pregnant or lactating patient
  7. Unstable arrhythmia
  8. Patients currently receiving with exception of up to 10 mg Prednisone equivalents daily
  9. Patients currently receiving chronic dialysis
  10. Patients currently receiving Extracorporeal Membrane Oxygenation (ECMO)
  11. Presence of any active (except non-melanoma skin cancer)
  12. Moderate to severe liver disease ( and ALT >5 X )
  13. Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen at rest
  14. Septic Shock (with >1 vasopressor)
  15. Multi-organ failure
  16. Not expected to survive > 48 hours
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Treatment

    Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100±20 x106 UC-MSC.

    Biological: Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC.

  • Placebo comparator
    Control

    Controls will receive two infusions of vehicle solution.

    Other: Controls will receive two infusions of vehicle solution.

Interventions

  • BiologicalSubjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC.

    Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100±20 x106 UC-MSC.

  • OtherControls will receive two infusions of vehicle solution.

    Subjects in the control group will be treated with two IV infusions of vehicle solution.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Alive and Free of Respiratory Failure

    The proportion of participants who are alive and free of respiratory failure following treatment with UC-MSC therapy.

    Time frame: 60 days

Secondary outcomes

  1. 1. All-Cause Mortality

    Number of Participants Who Died (All-Cause Mortality)

    Time frame: 60 Days

  2. 2. Survival Status

    Number of Participants Alive at Day 31

    Time frame: 31 Days

  3. 3. Incidence of Serious Adverse Events (SAEs)

    Number of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: 31 Days

  4. 4. Serious Adverse Event-Free Survival

    Number of Participants Alive Without Serious Adverse Events

    Time frame: 31 Days

  5. 5. Time to Clinical Recovery

    Time to Clinical Recovery (Days)

    Time frame: Up to 60 Days

  6. 6. Time to Oxygen Requirement ≤ 40%

    Time to Oxygen Requirement ≤ 40% (Days)

    Time frame: Up to 60 Days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Oct 2027, 7 months later.

Of 39 phase 3 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 7 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Jul 2026 → Mar 2027, primary completion Dec 2026 → Oct 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 18, 2026
StartEst.
Mar 1, 2027was Jul 2026
Primary completionEst.
Oct 31, 2027was Dec 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Mar 1, 2027
Oct 1, 2026
Primary completion
Dec 2026→Oct 31, 2027
Oct 1, 2026
Study completion
Dec 2026→Dec 2027
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Jul 2026→Mar 1, 2027
    Primary completion Dec 2026→Oct 31, 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07479043
Lead sponsor
Breathe Biologics, Inc.
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion